BioSpace News Archive

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 41st Annual Virtual Global Healthcare Conference on Wednesday, June 10, 2020 at 1:20 p.m. ET . Peter H. Griffith , executive vice president and chief financial officer, and David M. Reese , M.D., executive vice president of Research and Development at Amgen will present

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the closing of its initial public offering of 10,350,000 shares of common stock, which includes the exercise in full by the underwriters o

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the dou

Universal Health Services, Inc. (NYSE: UHS) announced today that Steve Filton , Executive Vice President and Chief Financial Officer will present at the following virtual conferences: Thursday, June 11 at 1:20p.m. (ET) at the Goldman Sachs 41 st Annual Global Healthcare Conference. Tuesday, June 23, 2020 at 2:00p.m

Castro Valley Health, Inc. has become aware of a data security incident that may have involved some personal information of former patients.

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce the Company will host a Corporate Update Conference Call and Webcast on June 10th, 2020 at 9 am MT/11 am ET.

Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product.

The sessions may be accessed from the “Investors & Media” page of Regeneron’s website at http://investor.regeneron.com/events-and-presentations.

OPTI Medical Systems, Inc., a subsidiary of IDEXX Laboratories, Inc., announced that it has received the CE mark certification in the European Union for its OPTI® SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19.

Abiomed announces the United States Food and Drug Administration has approved the company’s investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French Impella ECP™ heart pump.